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Abstract 
Upconverting nanoparticles (UCNP) were characterized for their properties as 
siRNA transfection agents, in an approach to target superoxide dismutase 1 (SOD1), a 
protein implicated in all forms of amyotrophic lateral sclerosis. In this study, two UCNP 
designs were considered and tested: (1) NaYF4:Yb,Er@NaYF4 core/shell nanoparticles 
with polyethylene imine (PEI) coating and (2) NaYF4:Yb,Er@CaF2 core/shell 
nanoparticles with a citric acid/PEI coating. The NaYF4-shell particles exhibited a 
working range less than 20 µg/mL to maintain 80% cell viability in HeLa cells. 
Additionally, these particles exhibited effective plasmid and siRNA delivery, quantified 
through green fluorescent protein (GFP) expression and SOD1 knockdown in Western 
blots respectively. The CaF2–shell particles had a greater working range, up to 50 µg/mL 
at 80% cell viability, but did not demonstrate effective plasmid or siRNA delivery. 
Continued research will be required to optimize a UCNP design which combines high 
cell tolerance with efficient payload delivery.   
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Chapter 1: Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized 
by degeneration of afferent neurons in the motor cortex, brainstem, and spinal cord. ALS 
is progressive and fatal; patients present with symptoms of muscle weakness and 
paralysis. The disease is fatal 3 to 5 years after diagnosis (Mitchell, 2007). No effective 
treatment exists for ALS patients, presenting a great need for an innovative therapy.  
Recent research has focused significant effort on one protein in particular, 
superoxide dismutase 1 (SOD1), because it is the most common factor associated with 
ALS (Grad, 2011). Mutated forms of SOD1 have been genetically linked to 20% of fALS 
cases, (Rosen, 1993) and misfolded SOD1 has been found in the spinal cords of all ALS 
patients; implicating SOD1 universally in the disease. (Forsberg, 2010)          
Small interfering RNA can be developed to specifically target messenger RNA, in 
order to silence target proteins. In the case of ALS, silencing mutant or misfolded SOD1 
may halt the progression of the disease. This potential offers an alternative approach to 
ALS treatment, but would require the introduction of siRNA molecules into the afferent 
motor neurons. Current siRNA delivery methods are not suitable for this application, 
mainly due to toxicity (Luo, 2000). 
Upconverting nanoparticles (UCNPs) represent a novel platform for siRNA 
delivery that may contribute additional functionalities during treatment. These may 
include tissue imaging, particle tracking, cell targeting, and cell penetration. If UCNPs 
could be optimized for siRNA delivery, they may provide the first effective foundation 
for ALS treatment. 
In subsequent chapters this project will elaborate on the potential utility of UCNPs 
for siRNA delivery, our project strategy, alternative designs, and design verification. 
Furthermore, experimental results will be described and discussed to validate UCNP 
designs for siRNA delivery. From these, conclusions will be drawn and recommendations 
made for future studies.  
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Chapter 2: Literature Review 
Amyotrophic Lateral Sclerosis  
 Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized 
by degeneration of the afferent neurons in the motor cortex, brainstem, and spinal cord. 
ALS is progressive and fatal; patients present with symptoms of muscle weakness, 
paralysis, dysarthria and dysphagia (difficulty speaking and swallowing, respectively), 
and ultimately respiratory compromise. The degeneration of the corticospinal motor tract 
causes the denervation in muscle fibers that induces this fatal muscle atrophy (Mitchell, 
2007). Other names for ALS include Motor Neuron Disease, Charcot’s Disease, and, Lou 
Gehrig’s Disease.  
 ALS can manifest in two ways; either as the limb-onset or the bulbar-onset form of 
the disease. In limb-onset ALS, the primary symptoms are first seen in the arms and legs; 
whereas with bulbar-onset, the disease first affects the muscles associated with speaking 
and swallowing.  Patients develop symptoms of both forms as the disease progresses, 
although ordinarily one form takes precedence. For about two thirds of patients, initial 
symptoms indicate limb-onset ALS. Survival after diagnosis for the limb-onset form is an 
estimated 3 to 5 years and for bulbar-onset patients, survival is typically 2 to 3 years. 
(Wijesekera, 2009)   
 Further characterization of ALS can be made based on its origin; either sporadic 
(sALS) or familial (fALS). Sporadic ALS refers to the seemingly random development of 
the disease, as the risk factors are not clearly identified. Familial ALS is genetically 
induced, and can be inherited. The average annual incidence of ALS between Europe and 
North America is reported as 1.89 per 100,000 (Worms, 2001).  In the United Sates, 
there are an estimated 5,000 new diagnoses each year (NINDS, 2011).  Of these cases, 
5-10% are familial (fALS) by autosomal dominant inheritance, and an estimated 20% of 
fALS cases are directly linked to a mutation in the Superoxide-Dismutase 1 (SOD1) gene 
(Wijesekera, 2009). 
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Etiology  
 The etiology and risk factors that induce ALS are not yet identified, though many 
potential pathways to the disease have been identified. Two major, interrelated 
mechanisms that contribute towards ALS are glutamate excitotoxicity and oxidative 
stress. 
 Oxidative stress damages proteins, lipids, and DNA within the cell. The formation 
of superoxide radicals (O2-) within the cell occurs naturally; most frequently at the 
mitochondria where electrons in the electron transport chain ‘leak’ onto molecular 
oxygen. The cell has natural anti-oxidant mechanisms to reduce these potentially harmful 
radicals, notably the SOD1 enzyme. However, without functional superoxide scavenging, 
reactive oxygen species can accumulate, resulting in the aforementioned cellular damage. 
Figures 1 and 2 demonstrate the role of normal SOD1 in a neuron (Figure 1), and the 
consequences of mutant SOD1 (Figure 2). One specific reactive oxygen species, 
peroxynitrite (ONOO-), forms in a reaction between superoxide and nitric oxide (NO-). 
Post-mortem studies have identified peroxynitrite-mediated oxidative damage in both 
sporadic and familial ALS patients, linking oxidative stress directly to ALS (Barber, 
2006).  
Figure 1: Normal SOD1 function in neuron 
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 Another study also suggested oxidative stress played a role in the inactivation of 
glutamate transporters (Trotti, 1999). Glutamate serves as an excitatory neurotransmitter 
in the central nervous system (CNS) and its neurotransmission is mediated by receptors 
in the synaptic cleft.  Excess accumulation of glutamate in the cleft can induce 
excitotoxicity; the over-activation of neurons resulting in cell death. This excitotoxic 
mechanism has been implicated in ALS, as well as other neurodegenerative disorders 
such as Alzheimer’s and Huntington’s disease. Many studies have focused on the 
Excitatory Amino Acid Transporter (EAAT) 2, for its major role in glutamate removal. 
One study utilized ALS mouse models to compare grip strength with ALS mice that over 
expressed EAAT2, and found that strength was significantly prolonged. However, neither 
lifespan nor paralysis onset were improved, suggesting that glutamate excitotoxicity 
contributes to ALS but is not the underlying cause. (Guo, 2003) 
 
Figure 2: Consequences of mutant SOD1 in neuron 
 The interrelation between these pathways demonstrates the complex, multifactorial 
etiology associated with ALS.  Additional mechanisms have been proposed and studied 
such as calcium-dependent mitochondrial dysfunction (Jaiswal, 2009), protein 
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aggregation (Mitsunori, 2001), and deficient neurofilament-mediated axonal transport 
(Williamson, 1999), and in each of these studies, mutant SOD1 was implicated.    
Superoxide Dismutase 1  
 Cu, Zn-superoxide dismutase (SOD1) is a superoxide scavenger found in the 
cytoplasm of most human cells. Normally, it is part of the family of oxidoreductases 
acting on superoxide radicals as the acceptor (Enzyme Classification Number: EC 
1.15.1.1). Disproportionation, also called dismutation, is the simultaneous oxidation and 
reduction of reagents. (IUPAC, 1997) Oxygen free radicals are a natural intermediate of 
intracellular chemistry. A constant low-level concentration of these species is maintained 
in the cytosol through the work of anti-oxidants and free-radical scavenging enzymes 
such as SOD1. (Shaw, 1997) 
 Aberrant SOD1 is the most common factor associated with ALS. (Grad, 2011) 
Mutated forms of SOD1 have been genetically linked to 20% of fALS cases. (Rosen, 
1993) Novel antibodies have revealed misfolded SOD1 in the spinal cords of both fALS 
and sALS patients; implicating SOD1 universally in both forms of the disease. (Forsberg, 
2010) In the case of fALS, both missense and nonsense mutations have been associated 
with SOD1 misfolding leading to disease pathology. (Pasinelli & Brown, 2006) In sALS, 
the cause of SOD1 misfolding is still unknown. However, recent studies have shown that 
oxidized forms of SOD1 and mutant forms share an aberrant conformation pointing to a 
potential pathology. (Bosco, 2010) 
 Whether in the mutated form or in the misfolded form, SOD1 toxicity is twofold. 
Toxicity is primarily attributed to a loss of specificity in the binding pocket, which leads 
to aberrant redox chemistry. (Pasinelli & Brown, 2006) Toxicity is also attributed to the 
mis-localization of the toxic enzyme. The toxic enzyme is moved to different organelles 
within the cell and secreted outside of the cell. This toxicity is multi-factorial as the 
SOD1 mis-localization within the cell, specifically within motor neurons, adversely 
affects a number of different processes including: DNA and RNA metabolism; vesicle 
trafficking in the Golgi apparatus; ATP production and calcium buffering in the 
mitochondria; axonal transport and neurofilaments; and proteasomes. Stress on the 
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proteasomes, mitochondria, and endoplasmic reticulum (ER) signals caspase activation 
and apoptotic pathways ultimately bringing about neuronal death. (Pasinelli & Brown, 
2006) SOD1 mis-localization outside of the neurons due to monomerization of misfolded 
proteins causes protein aggregation outside of the cell. These protein aggregates can 
undergo macropinocytosis and induce misfolding of native SOD1, thereby propagating 
the toxic effects along the spinal column. This is a potential cause of the progressive 
nature of ALS. (Grad, 2011) The ubiquitous implication of SOD1 across all forms of 
ALS suggests that it may be a universal and effective target for development of 
treatment.  
Current ALS Treatments 
 Only one drug, Riluzole, has been approved by the FDA for treatment of ALS, 
although other experimental drugs are currently in phase II and III trials. The therapeutic 
efficacy of these drugs is uncertain and improvements in survival are marginal at best, 
justifying the need for novel and innovative new therapies.  
 Riluzole, 2-amino-6-(trifluoromethoxy)benzothiazole, is hypothesized to inhibit 
glutamate transmission, offering the potential to minimize toxic, post-synaptic glutamate 
accumulation. Though the mechanism of action is unknown, Riluzole was found to be 
safe at doses of 200mg in phase I clinical trials. A double-blinded, placebo-controlled 
study conducted in 1994 examined 155 patients with both limb-onset and bulbar-onset 
ALS. After one year, patients whom received Riluzole had a median survival rate only 83 
days longer than patients in the placebo group (532 vs. 449 days). (Bensimon et al., 1994) 
 Currently in phase III trials, Ceftriaxone has been publicized by the ALS 
Association as another potential drug for ALS therapy. Ceftriaxone is an antibiotic of the 
β-Lactam antibiotic family; these antibiotics are known to induce expression of EAAT2, 
the main glutamate transporter in glial cells of the central nervous system (Miller, 2005). 
If successful, this approach would minimize post-synaptic glutamate accumulation and 
prevent excitotoxicity-induced neuron death. Currently, the US National Institutes of 
Health that are conducting the trial have not published any results. 
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 Dexpramipexole is another drug currently in phase III clinical trials, though no 
results have been published. In phase I and II trials, dexpramipexole was safe at doses of 
150 mg twice daily (Biogen Idec, 2011). It is the R enantiomer of pramipexole, a 
dopamine agonist used to treat Parkinson’s Disease. The R enantiomer, dexpramipexole, 
has no dopaminergic effects but is hypothesized to improve mitochondrial function and 
treatment has resulted in prolonged survival in ALS mice (Zinman, 2011).  
 Thus, for patients with ALS, there is a need for an alternative therapy. The only 
FDA approved drug, Riluzole, marginally increases lifespan, though no therapy exists to 
improve the quality of life or slow the progression of the disease. The identification and 
limited understanding of SOD1’s role in ALS presents an opportunity to treat what may 
be the major underlying cause of the disease. Until now, treatments have targeted 
downstream effects of aberrant SOD1 function; by disrupting the expression of genes 
encoding SOD1, disease progression could potentially be halted. The application of RNA 
interference may allow for knockdown of mutant SOD1 gene expression, and thus a new 
approach in ALS therapy. 
RNA Interference  
 Since the discovery of endogenous cellular pathways of messenger RNA regulation 
in plants and the elucidation of double-stranded RNA interference (RNAi), the potential 
of microRNAs (miRNAs) for therapeutic application has been widely studied. The 
efficacy of RNAi as a therapy has been extensively documented in laboratory animals, 
but has not gone beyond phase I clinical trials in humans (Grimm, 2007). The basic 
mechanism can be broken down into two pathways each beginning with small hairpin 
RNA (shRNA). The miRNA is produced either endogenously in the nucleus, or 
exogenously and delivered into the cell by artificial means. Endogenous miRNA goes 
through a two-stage modification prior to exiting the nucleus including RNA polymerase 
II or III and the Drosha complex. Exogenous, or synthetic, miRNA is designed to mimic 
this mature form, shRNA (Paddison, 2008). 
 Once in the cytoplasm, the shRNA, or double-stranded RNA (dsRNA), is acted 
upon by Dicer, an enzyme which cleaves off its loop structures producing a small 
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interfering RNA (siRNA). siRNA signals the inhibition, degradation, or cleavage of a 
specific mRNA. This target mRNA is determined by complementation with one of the 
two strands of the siRNA, which allows incredible specificity in targeting a specific 
mRNA sequence using this mechanism. This activity is carried out when the siRNA 
complexes with the RNA-induced silencing complex (RISC). It is the RISC that actually 
carries out the activity involved with RNA interference but it is the siRNA sequence that 
determines the target (Paddison, 2008). 
 Based on this system, siRNA can be developed using complementary base pairing 
with a target mRNA. This treatment is specific to the point that it can even target mutant 
versus wild-type strands of mRNA and thus correct autosomal dominant strains of 
genetically-based diseases by knocking down the mutant-type mRNA and allowing the 
wild-type to be expressed. One remaining challenge is the development of a mechanism 
to deliver siRNA into target cells. 
Current siRNA Delivery Vectors  
 In the past thirteen years, four primary methods of siRNA delivery have been 
developed: (1) viral vectors, (2) electroporation, (3) chemical modification, and (4) 
transfection. (Chen, 2010) Each method has its own benefits and limitations. These need 
to be explored in order to decide upon the method best suited to neuronal delivery.  
 Viral vectors have been used extensively in biotechnological applications for the 
introduction of RNA- and DNA-based exogenous materials (Luo, 2000). For siRNA 
delivery systems, the best-suited vectors are retroviruses, adeno-associated viruses, and 
lentiviruses. (Shi, 2003) The benefits of viral vectors are high efficiency and 
reproducibility, effective delivery into primary and non-dividing cells, and stable 
expression in vivo. The limitations of this vector include immunogenic response of the 
host organism, mutagenic properties of the host virus, and generation and titration of 
virus particles. (Chen, 2010) Recent studies have shown that retrograde transport of viral 
vectors through the motor neurons via muscular injection did not transport the therapy 
into the central nervous system. (Towne, 2011) 
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 Electroporation is a technique developed in vitro that has only recently been studied 
for in vivo applications. Electroporation utilizes a voltage pulse applied across the 
membranes of the target cells to open up pores in the membrane that will allow the entry 
of siRNA molecules. The benefits of electroporation are that it is noninvasive and it does 
not induce nonspecific immune responses. The limitations are that pulse conditions need 
to be optimized based on tissue density and depth, and that the cells near the sites of pulse 
application can be damaged by the electrical current. (Chen, 2010) 
 Chemical modification involves covalently linking specific targeting or protection 
molecules to the siRNA itself to allow for transport into cells. This is achieved either 
through the modification of specific bases at the ends of the siRNA or the addition of 
lipids to the 3’ end of the siRNA. The benefit of this vector is that the modified siRNA 
exhibits improved resistance to nuclease degradation compared to unmodified siRNA. 
However, two major limitations are the reduction in the activity of the modified siRNA 
and the production of toxic chemicals (Luo, 2000) upon the degradation of a modified 
siRNA molecule. More research is still being done to optimize this delivery vector. 
(Chen, 2010) 
 Transfection is the use of lipids, polymers, or other conjugates to encapsulate and 
deliver siRNA (Luo, 2000). The siRNA is typically encapsulated in a micelle or other 
similar structure and then brought into the cell through clathrin-mediated endocytosis. 
The benefits of using transfection agents are their high efficiency and reproducibility and 
their ease of use in most cell types. The limitations are that they can lack cell specificity, 
lipid-based approaches tend to disrupt function of the cell membrane while other 
approaches can invoke an immune response, and the size of the particles are hard to 
control. One commercially available lipid-based transfection agent, Lipofectamine™ 
2000, has demonstrated excellent transfection efficiency, although it is also cytotoxic 
(Clements, 2007).  
 Combining the technologies of chemical modification and transfection with the 
newer field of nanotechnology has led to a novel approach that safely and effectively 
delivers siRNA while introducing other functionalities. The entrance of nano-scale 
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therapeutics into pharmaceuticals began with the development of biologically active 
polymers. (Duncan, 2003) Polymers such as polyethylene glycol (PEG) form the basis for 
polymer-treatment conjugates. The polymer acts as a vessel to transport and protect the 
therapeutic molecule of interest. Once these conjugates were scaled down to the single 
molecule level, nano-scale therapeutics was born. Polymer chemistry allowed for the 
formation of targeting structures, polymeric drugs, polymer-protein conjugates, polymer-
DNA complexes, and polymeric micelles. (Duncan, 2003) This was joined by inorganic 
nanoparticles based on heavy metal and metalloid chemistry, typically gold or silver and 
silicon, used for their unique optical properties and biocompatibility. (Hirsch, 2003) More 
recently, attempts have been made to combine these two approaches by using a core-shell 
particle of inorganic material surrounded by a surface coating of polymeric and/or 
biological molecules resulting in multifunctional nanoparticles (NPs). (Ferrari, 2005) The 
organic surface coating creates an affinity for biological molecules. This can be used 
similar to transfection for transporting nucleic acids, i.e. siRNA, into target cells. 
Nanoparticles as Transfection Agents  
 Multifunctional nanoparticles (NPs) make it possible to combine cell targeting 
molecules, surface-interface lipids, treatment molecules, and optical activity into a single 
platform. (Serda, 2011) By conjugating the active molecules to the surface of the 
inorganic particle, NPs have the potential to overcome the common limitations associated 
with other transfection methods, specifically immune response and membrane disruption 
(Massich, 2009). However, NPs do present their own challenges. 
 A primary challenge is targeted and controlled release of the therapeutic molecule. 
Depending on payload interaction, typically electrostatic stacking interactions or covalent 
linkage, the NP will demonstrate different release profiles. With electrostatically coupled 
molecules, the release is dependent upon diffusion within the surrounding environment. 
Once the particle enters an environment that is more electrostatically favorable, the 
payload is released. With covalent linkage, the release is steadier; as the particle coating 
interacts with degradative enzymes, the payload is slowly released from the surface. 
(Duncan, 2003) 
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 Controlled release is achievable through controlled surface chemistry or external 
triggers. (Ferrari, 2005) By studying the electrostatic environment into which release is 
desired, NP surfaces can be tailored to the target. The difficulty becomes that this surface 
may not be the most favorable for interacting with the payload, so release must be 
balanced with dosage. With covalent linkage, it is possible to use electromagnetic 
radiation (EMR) to release the treatment molecules once the particle has reached the 
desired location (Serda, 2011). Resonance frequencies are used to excite the bond 
attaching the treatment molecule to the particle. Once the proper wavelength and 
frequency are determined, external EMR is used to stimulate the bond until release is 
achieved. This is typically achieved with lasers. The difficulty with this method is 
ensuring that the external signal is strong enough to release the treatment and yet weak 
enough to not damage native molecules. (Serda, 2011) 
 One secondary challenge is tracking NPs once they have been introduced into a 
tissue culture or organism. A simple solution is to tag the surface with fluorescent 
molecules. There are two major types of fluorescing molecules, endogenous and 
exogenous fluorophores. (Lakowicz, 2006) Both of these types of molecules typically 
need an external stimulus for activation. An incoming photon excites the electrons of the 
fluorophore causing it to jump to a higher energy state. As the electron loses energy, it 
moves back to a lower energy state and emits a photon with equal or lower energy than 
the original. (McQuarrie, 1997) This means that molecules that emit photons in the 
visible range will need to be stimulated in the visible (400-740 nm) or ultraviolet (UV,1-
400 nm) spectra, a range that can be disruptive to biological molecules. Additionally, 
biological tissues typically absorb in the visible and UV spectrum making penetrance 
difficult for larger cross sections of tissue. (Lakowicz, 2006) For exogenous fluorophores 
such as cyanine dyes, conjugation to the surface usually inactivates the fluorescence and 
so the molecule must be released from the surface before detection. (Congdon, 2010) 
Upconverting Nanoparticles (UCNPs)  
 Upconverting Nanoparticles (UCNPs) are core/shell nanoparticles that incorporate 
lanthanide metals to provide fluorescent properties. Lanthanide metals absorb in the 
infrared (IR) range (0.74-300 μm) and fluoresce in the IR, visible, and UV ranges. 
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Coupling specific metals within the UCNP core yields an upconversion of the incoming 
photon. This enables the potential to use low energy lasers in the IR range, that will not 
affect the tissue surrounding the particle, to the release molecules coupled to the particle 
itself (Han, 2009) This also provides a method of tracking the particle as it moves 
through the organism. Biological tissues typically absorb in the visible and UV spectra. 
Since Lanthanide metals can fluoresce in the IR range, the signal will not decay as it 
passes through the tissue. 
 The core consists of a base of sodium yttrium (III) fluoride (NaYF4) ceramic that is 
doped with various concentrations of ytterbium (Yb) and either erbium (Er) or thulium 
(Tm). The Yb acts as a photon acceptor excited at 980 nm. It then passes the energy to 
either Er or Tm. As more energy is passed to Er or Tm, the electrons are pushed to higher 
energy states and photons are emitted anywhere in the range of 900-400 nm, which is 
controlled by the doping ratios of Yb to Er or Tm. This core is surrounded by an 
electropositive, fluorescently inert shell. The positive shell is used for conjugation of 
organic materials, such as lipids, proteins, or polymers. It is this outer coating that 
interacts with biological surfaces and other molecules of interest.  
 
 The design team proposed to utilize UCNPs as siRNA delivery vectors for the 
targeted knockdown of SOD1. UCNPs were assessed for their utility as transfection 
agents. The cytotoxicity and transfection efficiency associated with UCNPs were 
characterized in vitro. HeLa human cervical cancer cells were used to conduct these 
characterizations through a variety of standard biochemical assays. 
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Chapter 3: Project Strategy 
Initial Client Statement and Objectives 
 
Given the potential of siRNA therapies for the treatment of ALS, and the platform 
of UCNPs as transfection agents, the team developed an initial client statement: 
To develop a siRNA delivery system that is safe and effective based on the platform of 
upconverting nanoparticles for treatment of ALS. 
 Before the team could put forward a design, several steps had to be taken. First, 
the stakeholders had to be identified. These stakeholders would then define the objectives 
and constraints of the delivery system. These criteria are essential to the construction of a 
design space that meets the requirements of all parties involved while providing 
flexibility for the team to explore all possible solutions to the problem presented. 
The stakeholders were broken down into three primary groups: users, clients, and 
designers. The users are defined as any persons utilizing the delivery system for the 
knockdown of target proteins. The short-term users include graduate students and the 
principal investigator, Dr. Gang Han, while the long-term users include medical doctors, 
nurses, and patients. The users were considered the main stakeholders in this process. The 
clients included Dr. Gang Han and his research team, and the design team (Steven 
Buchholz and Sam Kesseli). 
Each stakeholder group contributed different objectives to the design. The users 
desired a safe and efficacious design that is easy to use and cost-effective. The clients 
desired a design that would be specific and scalable for continuing the project into animal 
models. From these, the design team further defined sub-objectives to better measure the 
outcomes of the design and to ensure that the design criteria were met (See Appendix A: 
Objectives Tree). These were then discussed with the users and clients to rank the 
importance of each of the objectives and sub-objectives. 
Through pairwise comparison, the relative priority of each objective was 
determined. The Pairwise Comparison Chart (PCC) is a valuable tool for determining the 
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priority of objectives. The calculation is binary, so results only indicate which objective 
is more or less important; it does not gauge how much more or less important the 
objectives are relative to one another. The PCC for the primary objectives indicates that 
“specificity” is the highest priority, while “efficacy” is of lowest priority. See Table 1 
below for the PCC analysis. Each primary objective is listed below by priority. 
Table 1: PCC for Design Objectives 
 
1. Specificity was identified as the most important among the objectives.  
Specificity was defined by two parameters: specific cell penetration (targeting) 
and specific gene silencing. Of these two, specific gene silencing holds the 
highest priority. That is, if the target gene of interest (SOD1) is not accurately 
silenced, the design fails.  
2. Scalability is the second-highest ranking objective of the design. The design 
should be scalable in three aspects (in order of priority): scalable to in vivo 
studies, to alternate cell lines, and to different dosages. To succeed as a therapy in 
ALS patients, the design should satisfy these sub-objectives.  
3. Safety is third in the ranked objectives. Although all therapies have side effects, 
the final design must not cause more harm to the patient than the disease itself, 
and be non-toxic. Additionally, applying the therapy should pose minimal risk to 
the administrator.  
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4. Efficacy will only be relevant if the first three objectives are effectively met. If 
the therapy is minimally effective, but remains safe, scalable, and specific, the 
design will be considered successful. An efficacious design will be comparable to 
other delivery methods currently used in laboratory settings, will show broadband 
cell penetration, and will consistently present a measurable degree of SOD1 
knockdown. 
Constraints  
The design constraints listed below were identified in collaboration between the 
clients and the design team. These constraints must be met in full to complete the 
design successfully.  
1. Must be less cytotoxic than Lipofectamine™ 2000 
2. Must have positive surface charge 
3. Must incorporate UCNP’s 
4. Must deliver siRNA 
5. Must be completed by March 2012 
Revised Client Statement  
“To design, develop, and optimize an siRNA delivery system based on the 
platform of lanthanide-doped UCNPs that is specific to the target protein and 
target cells, scalable to in vivo models and multiple cell lines, safe (less 
cytotoxic that LipofectamineTM 2000) and efficacious in comparison to 
standard transfection agents for sequence-specific knockdown of SOD1, a 
gene linked to fALS. Additional functionalities should include cell targeting 
and penetration, and siRNA protection from RNase for in vivo siRNA 
tracking.” 
Design Approach: Experimentation  
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 To effectively evaluate the preliminary and final designs for a siRNA delivery 
system, a standardized battery of laboratory tests was performed. The fulfillment of each 
objective was gauged by the outcome of these tests. Below are descriptions for each of 
the major experiments performed, and their measurable outcomes. They are described in 
the order they were performed. 
 The MTT assay, named for its active reagent, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, is an in vitro assay used to determine cell viability, and will 
serve as the measure of safety for the design objectives. The test measures the cellular 
conversion of the tetrazolium salt into a formazan dye product. After four hours 
incubation time with MTT, a stop solution (SDS diluted in HCL) is added to solubilize 
the formazan product. The quantity of soluble formazan dye is directly proportional to the 
quantity of viable cells.  In a cell culture plate, the absorbance of solubilized samples 
can be read at an absorbance of 570nm, thus quantifying the cytotoxic effects of the 
design and the experimental dose. 
 Agarose gel electrophoresis enables the determination of the optimal ratio of 
plasmid DNA to NP for transfection. Nanoparticle/DNA aliquots were loaded into the gel 
at varying ratios. During electrophoresis, excess, unbound DNA moved down the lanes of 
the gel. Ethidium Bromide (EtBr) intercalating agent can be used to label the plasmid 
DNA. Quantification of the band intensity for each lane enabled the design team to 
determine the ratio where the NPs first bind 100% of the DNA, leaving no measurable 
unbound DNA in the lanes of the gel.  
 A spectrofluorometer was used to determine the RNA-Nanoparticle binding ratio. 
First, RNA is exposed to EtBr (Excitation: 540 nm, Emission: ~590 nm) to determine 
baseline fluorescence. Nanoparticles were incrementally added, which upon binding with 
RNA, freed the EtBr. The ratio of particle to RNA concentration was determined when 
the fluorescence first reached a minimum; at this point the maximum quantity of RNA 
was bound to particles, rather than the fluorescent EtBr. (See Figure 3) This specification 
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enabled the design team to optimize the nanoparticle:RNA ratio. 
 
Figure 3: RNA Titration Schematic 
 Transfection with green fluorescent protein (GFP) plasmid served as a proof-of-
concept to test the efficacy of the nucleic acid delivery mechanism and provided a means 
to directly compare the design to the control, Lipofectamine. In a GFP transfection, 
plasmid DNA containing the sequence for GFP is taken into the cell. Expression of GFP 
by the cells produces a measureable fluorescent signal that correlates with transfection, 
enabling a direct comparison between delivery vectors.  
 Western blotting, also known as immunoblotting, allows the user to identify and 
quantify specific proteins in a tissue sample. Samples can be collected following siRNA 
transfection with experimental and control delivery vectors. After gel electrophoresis and 
transfer to a nitrocellulose membrane, proteins are identified by interaction with primary 
and secondary antibodies. The primary antibody binds specifically to the protein of 
interest. The secondary antibody binds to the primary antibody, which is conjugated with 
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a reporter, commonly horseradish peroxidase (HRP). When exposed to chemiluminescent 
agents, the HRP produces a measurable signal. The intensity of the signal can be 
quantified, and is directly correlated with the quantity of protein. Thus, in the context of 
gene knockdown, this technique tests both the specificity of the protein and the efficacy 
of the RNAi mechanism.  
 The protocols for these tests were developed and finalized through preliminary 
experiments, and remained consistent throughout the testing of the preliminary, 
alternative, and final designs. A final comparison and weighing of objectives enabled the 
design team to select a final design that best meets the objectives, and satisfies all 
constraints.   
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Chapter 4: Alternative Designs 
Needs Analysis  
 As discussed in Chapter 2, the only FDA-approved drug regimen for ALS patients 
is ineffective, justifying the need for a novel therapy. A design that utilizes RNAi to 
selectively silence mutant SOD1 mRNA will require consideration of several functions. 
Outlined below, the functions are divided into two categories: primary and secondary. 
Primary functions are those that fall within the scope of this MQP. Their achievement 
will be used to measure project success. The secondary functions are those that have 
potential to be incorporated with the final design, but will not be tested or evaluated in 
this report. 
Primary Functions:  
1. Protein silencing 
The design must ultimately silence the protein of interest. Research suggests that mutant 
SOD1 is in part responsible for the motor neuron death associated with ALS. Effectively 
silencing this protein may provide a therapy to ALS patients.  
2. siRNA delivery 
To utilize the RNA interference cellular mechanism, the design must deliver siRNA into 
the cell of interest. Successful delivery is critical to silence the target gene.  
3. siRNA protection 
Not only must siRNA be delivered, but it must be functional upon entrance into the cell. 
The design must therefore protect the siRNA from degradation while in the extracellular 
environment.          
Secondary Functions:  
1. Deep-tissue imaging 
 MQP Report 27 
The design should produce a readable signal from within in vivo specimens. This feature 
would allow for particle tracking and confirm that the therapy was delivered to a target 
location.  
2. Cell targeting 
The design should be functionalized to target a designated cell type. This would be 
necessary for in vivo applications to deliver the therapy only to cells of interest.  
Preliminary and Alternative Designs  
 Upconverting nanoparticles were identified as the fundamental design platform for 
their delivery efficacy, imaging potential, and highly tunable surface chemistry. The 
generic UCNP structure can be divided into three major components; core, shell, and 
conjugate. The core contains the lanthanide elements responsible for NIR photon 
upconversion. The shell and conjugate serve to enhance biocompatability and siRNA 
affinity, respectively.   
 Variation of the shell and conjugate layers will directly impact the efficacy of the 
UCNP as a siRNA vector. These components comprise the surface that directly interfaces 
with the target cells, thus size, shape, charge, and composition are variables to be given 
consideration. Furthermore, the chemical interaction between shell and conjugate is also 
of concern; weak bonding can have detrimental effects on cytotoxicity if conjugate 
polymers dissociate from particle surfaces. 
The preliminary nanoparticle incorporates an Yb, Er-doped core. The shell on the 
particle is a NaYF4 (hexagonal/cubic phase) crystal. Polyethyleneimine (PEI), a branched 
cationic polymer, was chosen as the conjugate. PEI was electrostatically bound to the 
particle surface, and is attracted to negatively-charged cell membranes, promoting 
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endocytosis. Additionally, the cationic property of PEI enables it to bind negatively-
charged siRNA, making it an effective (though toxic) transfection agent by itself. 
Previous experimentation by former rotation students identified the binding ratio as 4 
pmol siRNA to 1 μg NaYF4-shell NPs. With DNA plasmid, the mass ratio was optimized 
at 1 μg to 6 μg NaYF4-shell NPs. See Figure 4 for a schematic of the preliminary UCNP 
description.  
The second alternative design 
maintained the same core and shell as the 
preliminary design, with a different 
conjugate; oleic acid. This conjugate was 
considered as it has been reported to 
improve nanoparticle dispersability by 
increasing the hydrophobicity (Wang, 
2003). Dispersability may improve the 
transfection efficiency, as particle 
aggregation can limit the efficacy of siRNA 
Figure 4: Preliminary UCNP design fabricated by the Han Lab. These particles are NaYF4 
core/shell particles with Yb/Er doped cores. The shell is composed of NaYF4. Branched chain 
PEI was electrostatically bound to the shell as the conjugate to bind siRNA.   
Figure 5: Second UCNP alternative design – 
Oleic Acid coupled particle 
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vectors (Alshamsan, 2009).  Figure 5 
represents a conceptualization of this 
particle.  
 A third alternative design would 
combine both PEI and oleic acid onto 
the same core and shell. The aim of this 
approach would be to incorporate the 
desirable properties of PEI and oleic 
acid; transfection efficacy and 
dispersability. This would potentially enable the particle to bind with siRNA while 
minimizing aggregation. A conceptualization of this particle is demonstrated in Figure 6. 
A fourth alternative design incorporates a new shell around the same lanthanide 
doped core; CaF2. The surface chemistry associated with this shell provides one critical 
difference from the NaYF4-shell; it can bond with PEI polymers covalently rather than 
electrostatically. This alternative may enable the use of PEI for its suitable transfection 
properties, while improving the biocompatibility of the UCNP. Figure 7 represents this 
particle.  
Figure 6: Oleic Acid / PEI coupled UCNP 
Figure 7: Calcium fluoride shell UCNP with PEI 
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Preliminary Data  
 Several experiments were conducted to ensure the feasibility of the proposed 
design. These preliminary studies also served as a learning platform for the design team, 
and an opportunity to develop and customize all laboratory protocols. All in vitro 
experiments were performed using the HeLa cervical cancer cell line. Cells were cultured 
using Dulbecco’s Modified Eagle Medium (DMEM) at 5% CO2 and 37°C incubation. All 
nanoparticle stocks were synthesized and purified by Han Lab. For details on the 
synthesis, see Manufacturability of UCNPs in Chapter 6: Discussion. 
 The following tests (GFP-Plasmid Transfection, MTT cytotoxicity, and Western 
Blot) each provide quantitative measurements of how well the design meets the 
objectives. Preceding each figure, a brief discussion will outline the experimental method 
and interpretation of the data. 
Preliminary MTT Cytotoxicity Assay  
 To assess nanoparticle cytotoxicity, an MTT assay was performed using Promega’s 
CellTiter® 96 Non-Radioactive Cell Proliferation Assay according to the manufacturer’s 
instructions. Plated cultures were prepared on standard tissue culture polystyrene 96-well 
plates. Cells were seeded at a density of 7,500 cells/well in DMEM + 10% FBS, and 
incubated 24 hours before sample exposure. During sample loading, growth medium was 
aspirated and replaced with Gibco’s low serum Opti-MEM. NaYF4-shell nanoparticles 
were loaded into wells at increasing concentrations and incubated for 4 hours. As a 
comparison, NaYF4-shell particles were also mixed with plasmid and given 5 minutes to 
complex prior to loading. Medium was then aspirated and replaced with DMEM + 10% 
FBS and cells were incubated for 24 hours. MTT dye (15 μL) was added to each sample 
well. After 4 hours, 100 μL of solubilization solution was added to each sample well. As 
instructed in the protocol, the plate was sealed with parafilm and left for 24 hours at RT 
before measuring absorbance to allow the MTT salt to convert to its formazan product. 
Absorbance was read at 570 nm. For each concentration tested, n = 8.  
 Figure 8 displays the results of two separate MTT assays. The toxicity of the 
preliminary NaYF4-shell nanoparticle correlates with cell viability and is measured 
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against particle concentration. On the x-axis, particles are measured in micrograms per 
square centimeter of the tissue culture surface. Relative percent viability is a measure of 
cell viability compared to a control group (unexposed to nanoparticles). The data shown 
in red represents plasmid-coupled nanoparticles. The nanoparticles and plasmid form 
complexes through electrostatic stacking interactions. The plasmid-nanoparticle 
complexes were formed using the GFP Transfection protocol. The data in green 
represents unbound particles.  
 The data suggests that UCNP-plasmid interaction decreases nanoparticle 
cytotoxicity, in which is suggested by the plateau-like trend in the data. The data 
represented by the green line indicates that toxicity directly increases with particle 
concentration, as evidenced by the constant, negative slope that approaches <20% initial 
cell viability at concentrations greater than 26.67 micrograms of nanoparticles per square 
centimeter. The data represented by the red line indicates that the binding of DNA 
plasmid decreases the toxic effect of the nanoparticles. (Note: these two experiments 
were done on different plates but at the same time and under the same conditions) 
 

















NaYF₄ NPs (μg/cm²) 
PEI-NaYF₄@Yb,Er NPs: Unbound vs. 
Plasmid-Conjugated 
1:7 DNA:NPs (μg:μg) NPs
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GFP Plasmid Transfection  
 To quantify the efficiency of the preliminary NaYF4-shell nanoparticle, GFP 
plasmid transfection experiments were conducted in 96-well plates. The intensity of GFP 
fluorescent signal should correlate directly with transfection efficiency. Cells were 
seeded at densities of 7,500 cells/well in DMEM + 10% FBS, and incubated 24 hours 
prior to sample loading. During transfection, medium was aspirated and replaced with 
Gibco’s low serum Opti-MEM. Exposure time was 4 hours incubation, at which point 
medium was aspirated and replaced with DMEM + 10% FBS. Cells were incubated with 
plasmid for 48 hours. Before loading, plasmid was mixed with nanoparticle solution and 
allowed 20 minutes to form complexes. For Lipofectamine, 20 minutes was also allowed. 
GFP fluorescence was read at 24- and 48-hour time points. Figure 9 shows data from the 
48-hour reading. Each group was performed in octet for and n of 8. 
 Transfection with GFP plasmid serves as an evaluation of transfection efficiency. In 
this experiment, GFP plasmid concentration was fixed at 12 μg/mL and transfection was 
performed with the NaYF4-shell nanoparticles (84 μg/mL) and the control agent, 
Lipofectamine. The fluorescence intensity directly correlates with transfection efficiency.  
 In Figure 9, the y-axis represents the fluorescence for the samples, which is relative 
to the PBS control. This serves as an indication that the preliminary design achieves 
transfection efficiency at a level that is approximately 45% of that achieved using a 
liposomal delivery method.  
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Figure 9: Quantification of preliminary GFP plasmid transfection 
Western Blot Analysis  
 For Western blotting, samples were prepared from transfected cell populations 
cultured in 12-well plates. Cells were seeded at 90,000 cells/well in DMEM + 10% FBS 
and incubated 24 hours prior to transfection. Upon loading, media was aspirated and 
replaced with Gibco’s low serum Opti-MEM. Samples were prepared for PBS controls 
(100 μL), NP controls (7.5 μg), and a fixed NP-siRNA experimental treatment (7.5 μg to 
30 pmol). The samples were exposed to cells for 4 hours incubation, and then aspirated. 
Cells were left to incubate 72 hours before lysis and protein harvest. Lysis was performed 
using 200 μL Promega M-PER lysis buffer per well. The lysis buffer was supplemented 
with Thermo Scientific’s Halt Protease Inhibitor Cocktail. Samples were purified by 
micro centrifugation and stored at -20° C. Sample concentration was determined via 
Pierce BCA Assay and normalized during gel loading.  
A sample volume of 24 μL was added to 6 μL Lammeli loading buffer, for a total 
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130 minutes. Nitrocellulose was used for the transfer membrane, and transfer was 
conducted at 100V for 1 hour. Membranes were washed 3 times with PBS-Tween 
(PBST), and blocked in 5% milk-PBST for 1 hour prior to primary antibody incubation.  
Primary antibodies were added at 1:5000 and 1:500 dilutions for α-Tubulin (Sigma 
Aldrich, 010M4813) and SOD1 (Meridian, K90077C), respectively. Incubation occurred 
at 4O C for 24 hours. Blots were then washed in PBST, and incubated 1 hour in 5% milk-
PBST at room temperature. Dilutions for secondary antibodies were 1:10,000 for both 
proteins. Following secondary incubation, blots were washed in PBST a final time, and 
exposed with SuperSignal® West Pico Chemiluminescent substrate (Thermo Scientific, 
#34080). Imaging was completed with an ImageQuant LAS 4000 system. To analyze 
protein knock down, a ratio is calculated between the protein of interest (SOD1) and the 
control protein (α-tubulin). This accounts for the natural variation of protein 
concentration between samples, and enables calculation of a normalized, quantitative 
value for knockdown. 
 Figure 10 is one example (of 5 trials) of a Western blot membrane after 
chemiluminescent imaging. For each sample (three for each parameter) the top band 
represents α-tubulin, while the lower set of bands represent SOD1. One can see 
qualitatively that the bands in the experimental UCNP-siRNA lanes are less intense than 
those of the control samples. This serves as an indication that knockdown was achieved.  
 
Figure 10: Western blot from transfection with 7.5 μg NaYF4 -shell particle 
α-Tubulin 
SOD1 
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 Further analysis using ImageJ software was used to quantify band intensities. Each 
lane can be the measured independently for the intensity of the signal, which appears as a 
peak (black) in a background baseline signal (white). The area of the peak correlates 
directly with band intensity, enabling quantification of band intensity. Figure 11 displays 
the relative, average intensities for each sample set, and confirms the indication that 
SOD1 knockdown was achieved; approximately 55% less than a PBS control. This is not 
only a measure of design efficacy, but also its specificity; as SOD1 target protein 
expression appears to be inhibited.  
 
Figure 11: Quantification of SOD1 protein bands from Western blot shown in Figure 10. 
Each bar represents the average of 3 samples. Error bars represent 1 standard 
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Chapter 5: Design Verification  
Included in this chapter are the results of the experiments performed using the final 
nanoparticle design, the CaF2-shell nanoparticles. The CaF2 shell was hypothesized to offer 
increased biocompatibility, while still serving as an effective transfection agent. In the 
chronological order they were performed, the results include cytotoxicity data, plasmid binding 
ratio optimization, siRNA binding ratio optimization, GFP plasmid transfection, and SOD1 
siRNA transfection with Western blotting. Following each data figure, key quantitative features 
will be highlighted. 
The order in which these experiments were conducted was intentional. Cytotoxicity 
provided grounds for identifying the acceptable dose of CaF2-shell UCNPs to be used in 
transfection experiments. Binding ratio optimization was conducted prior to transfections to 
optimize the efficiency and delivery of the system. Having identified the acceptable toxic range 
and optimal particle conjugation, transfections could be performed with nanoparticle and siRNA 
doses which best met the design objectives of safety and efficiency. The objectives of efficacy 
and specificity were then evaluated with the GFP and siRNA transfection assays, respectively.  
Cytotoxicity  CaF2-shell NPs were added in concentrations of 10, 20, 30, 50, 100, 150, 200, 500, and 
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Figure 12: Final MTT cytotoxicity 
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control that received only PBS in lieu of NPs during loading. This data is shown in Figure 12.  
 
Figure 13: Comparison - final and preliminary toxicity  
In Figure 13 the data from CaF2-shell NP cytotoxicity experiments is compared with 
previous data from NaYF4-shell NP data from Figure 8 (note: experiments were performed 
independently). The data demonstrates that NaYF4-shell NP resulted in a more rapid decrease in 
cell viability as a function of nanoparticle concentration. For example, at a concentration of 30 
μg/mL, cell viability with the NaYF4-shell particle measured 69%. At this same concentration 
with the CaF2-shell particle, the viability measured 91%.  
Binding Ratio Optimization - DNA  
Optimization of the Plasmid-NP binding ratio was determined via agarose gel 
electrophoresis. A 3% agarose gel was prepared in Tris-Acetic acid EDTA (TAE) with 1 µL 
EtBr stock solution (10g/L). Two microliters of 6X Lammelli loading buffer was added to each 
sample. Samples were prepared in which mass:mass ratios between CaF2-shell UCNPs and 
plasmid DNA increased. The ratios (DNA:NP) evaluated were: 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 
1:70, 1:80, and 1:90. A plasmid DNA only (no NP) control was loaded in lane 1. For each 
sample, 20 µL was loaded into each lane. Two µL EtBr stock solution was added to the TAE 
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with an ImageQuant LAS 4000 system. The image can be seen in Figure 14. Results were 
prepared using ImageJ and Microsoft Excel®.  
 
Figure 14: Mass binding ratio of DNA plasmid to CaF2-shell NPs  
At the top of each lane, free (unbound) DNA appears as a visible band. When UCNPs bind 
DNA plasmid, the complex is too large to travel through the agarose gel, and remains in the well; 
the bands at the bottom of the gel. As the ratio approaches optimal binding saturation, DNA band 
intensity decreases as the quantity of free DNA decreases. As a result optimal binding occurs 
near the lane in which the free DNA signal is no longer detectable – which appears to occur at 
the 1:80 ratio. Figure 15 demonstrates an ImageJ quantification of the band intensity for free 
DNA. 
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Figure 15: Quantification of NP-Plasmid agarose gel  
Binding Ratio Optimization - siRNA  
Optimization of the NP-siRNA binding ratio was determined via NP titration into an 
Ethidum Bromide – siRNA solution. Ethidium bromide (2 µL of [1 mM] solution) was 
complexed with siRNA (10 uL of [20 uM] solution) in 1.998 mL PBS in a standard cuvette. A 
stock solution was prepared of equal EtBr and siRNA concentrations, and 2 µL UCNPs (0.1g/L). 
Titration was performed by adding stock solution to the cuvette in 10 µL increments (larger 
increments could be used in the plateau regions of the plot) until sample fluorescence reached a 
minimum. Fluorescence was measured using a FluoroLog™ spectrofluorometer, at an excitation 
wavelength of 545 nm.  Emission was recorded at 590nm. Titration was discontinued after 
fluorescence reached a steady minimum and results were prepared using Microsoft Excel®.   
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Figure 16: NP titration in siRNA-EtBr solution  
As shown in Figure 16, at 3.6 nM (marked in red) the plateau phase of minimum 
fluorescence is reached.  This minimum indicates that a maximum quantity of EtBr has been 
released and thus inactivated. Because the EtBr is released as siRNA binds to particles, this 
represents the point at which the optimal siRNA- CaF2-shell UCNP ratio is reached.  
Plasmid transfection  
 GFP plasmid transfection was performed using CaF2-shell UCNPs in varying ratios 
between 1:60 and 1:70 µg DNA : µg CaF2-shell UCNPs. Negative controls were prepared with 
PBS, CaF2-shell UCNPs only, DNA only, and Lipofectamine™ only. The positive control was 
prepared with Lipofectamine™ and DNA. The most notable result was that the NP transfection 
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Figure 17: Quantification of final GFP plasmid transfection  



















CaF₂-shell NPs GFP Transfection 
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Figure 18: Western blot with final design Qualitatively in Figure 18, a visible decrease in band intensity for the positive control lanes transfected with Lipofectamine™ occurred, although knockdown did not appear to be achieved with the nanoparticle transfection. Band intensity was quantified using ImageJ software, and knockdown evaluated as the ratio of SOD1 per the control, alpha-tubulin.   
 
Figure 19: Quantification of final western blot  
 


















 MQP Report 43 
 As shown in Figure 19, quantification suggested that SOD1 knockdown was not achieved 
with the CaF2-shell nanoparticles at any of the tested ratios. Follow up testing was conducted in 
an effort to obtain stronger chemiluminescent signaling, and reduce background noise. A new 
protocol was used to obtain samples of higher protein concentration, and a 15% polyacrylamide 
gel was utilized to allow better separation of the SOD1 protein.  
 Samples were prepared in 6-well culture plates, lysed using 400 μL Laemmli’s reducing 
buffer (2X), and were scraped off the plate using a spatula. Before gel loading, samples were 
ultra-sonicated. An adeno-associated virus carrying SOD1 gene was incorporated as a negative 
control in addition to the standard PBS control. The incubation period was reduced to 24 hours 
(instead of 72) due to time constraints. All other preparations were kept constant.    
Figure 20 represents the blot prepared with the modified method. Band intensity for SOD1 
was improved, although the background signal was relatively high. In addition the tubulin 
control bands were not clear because they remained in the stacking section of the gel. Most 
importantly, the SOD1 bands do not appear to exhibit any knockdown; similar to the result in 
Figure 18.  
-AAV +Lipo PBS     NP+RNA 1 2 3 
Figure 20: Western blot with modified protocol 
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Chapter 6: Discussion  
 In order to assess the characteristics of the different UCNP designs in terms of the 
objectives, each UCNP design was placed through a number of different experiments as detailed 
in the previous chapter. Each of these experiments is paired with a different objective. By 
bringing together the data from the different experiments, it is possible to evaluate the viability 
and effectiveness of the UCNP design as a transfection agent. In the following sections, UCNPs 
are discussed as a possible ALS treatment in terms of their economic, environmental, social and 
even political impact; safety, ethics, and sustainability; and manufacturability. 
Viability as Transfection Agent  
 Both UCNP designs were tested for toxicity using the MTT as an indicator of live cells. 
The more cells alive 20 hours after a 4-hour incubation, the less toxic the effect. The range of 
toxicity was then compared to the dosages needed for transfection to determine whether the 
UCNP is a viable option in terms of safety, defined as 90% viability of the cells or greater. 
 During the preliminary testing, NaYF4:Yb,Er@NaYF4 core/shell nanoparticles (NaYF4-
shell NPs) with a PEI coating were used for transfection. Cell viability of these particles showed 
a sharp drop-off beyond a concentration of 10 μg/mL, as shown in Figure 8. At concentrations of 
20 μg/mL or more, only 80% of the cells were still metabolically active within 20 hours of 
exposure to the NaYF4-shell NPs. Given the high concentrations typically needed for DNA 
transfection, this data seems to rule out these preliminary particles as a viable DNA transfecting 
agent. However, siRNA does not require such high doses, which allows for NaYF4-shell NPs to 
be assessed as a siRNA delivery system. 
The binding ratio for NaYF4-shell NPs with DNA plasmid was experimentally determined 
as 7:1 by mass to achieve effective transfection of DNA plasmid. The concentration of DNA 
plasmid used during transfection in a 96-well plate is 5 μg/mL. In order to transfect that 
concentration of DNA plasmid, 70 μg/mL of NaYF4-shell NPs was used. The cell viability at this 
high concentration for NaYF4-shell NPs alone is less than 20%. However, complexing of the 
particles to DNA seemed to have a protective effect. As seen in Figure 8, cell viability seems to 
plateau around 80% for NaYF4-shell NPs complexed to DNA plasmid at concentrations ranging 
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from 35 to 105 μg/mL. This accounts for the positive transfection results seen in Figure 9. GFP 
expression was observed using NaYF4-shell NPs for transfection at DNA concentrations ranging 
from 5 to 25 μg/mL. 
The binding ratio for NaYF4-shell NPs with siRNA was experimentally determined to be 
1:4 μg NPs to pmol siRNA to achieve effective knockdown. The concentration of siRNA used 
during transfection in a 12-well plate was 15 nM. In order to transfect that concentration of 
siRNA, 3.75 μg/mL of NaYF4-shell NPs needed to be used. The cell viability at this low 
concentration is well over 90% for NaYF4-shell NPs alone, therefore cell viability when using 
NaYF4-shell NPs for siRNA transfection should be above the acceptable threshold of 90%. 
During the verification process for the final design, NaYF4:Yb,Er@CaF2 core/shell 
nanoparticles (CaF2-shell NPs) conjugated to a citric acid-PEI coating were used for transfection. 
Cell viability for these particles showed a less dramatic drop-off beyond a concentration of 80 
μg/mL than NaYF4-shell NPs as shown in Figures 12 and 13. At concentrations lower than 80 
μg/mL, the cell viability for CaF2-shell NPs seems to stabilize around 80%. Cell viabilities of 
less than 20% were not observed until the concentration exceeded 150 μg/mL. This reduced 
toxicity at high concentrations enables a greater range of dosages for CaF2-shell NPs for both 
DNA and siRNA transfection. 
The binding ratio for CaF2-shell NPs with DNA plasmid was experimentally determined as 
80:1 μg NPs to μg DNA for maximal binding. Typically, the most effective ratio for transfection 
is somewhere beyond this point. As mentioned above, the concentration of DNA plasmid used 
during transfection in a 96-well plate is 5 μg/mL. In order to transfect that concentration of DNA 
plasmid, at least 350 μg/mL of CaF2-shell NPs would need to be used. The cell viability at this 
high concentration for CaF2-shell NPs alone is less than 20%. It is possible that the complexed 
DNA plasmid would have a similar protective effect for the cells as seen with the NaYF4-shell 
particles. Prior to determining the binding ratio of DNA plasmid to CaF2-shell NPs, a 
preliminary MTT assay was run using the binding ratio of the NaYF4-shell particles, 1:7. The 
data is shown in Figure 8. A similar protective effect was seen at CaF2-shell NP concentration 
ranging from 5 to 100 μg/mL. However, since the binding ratio used during transfection may be 
much higher, it cannot be definitively stated that this would be the case. 
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The binding ratio for CaF2-shell NPs with siRNA was experimentally determined to be at a 
1:30 molar ratio for maximal binding. The average concentration of siRNA used during 
transfection in a 12-well plate is 15 nM. In order to transfect that concentration of siRNA, a 
CaF2-shell NPs concentration of at least 0.5 nM would need to be used, which is equivalent to 22 
μg/mL. The cell viability at this low concentration is around 89% for CaF2-shell NPs alone, 
therefore cell viability when using CaF2-shell NPs for siRNA transfection is close to the 
acceptable threshold of 90%. 
When comparing the two particles, the CaF2-shell NPs are less toxic at a higher 
concentration but have a greater toxicity overall in that cell viabilities never exceed 90% whereas 
NaYF4-shell NPs have high toxicities at lower concentration but do have a small window where 
cell viability is greater than 90%. The complicating factor becomes the protective effect of the 
NP-nucleotide complex. If this protective effect is seen in both particles types and extends to 
both types of nucleic acid, then both the initial and final particle designs could be viable as 
transfection agents based on their toxicities. More testing is needed to demonstrate this 
experimentally. From here, it is necessary to compare the particles based on other objectives, 
namely specificity, scalability, and efficacy. 
Effectiveness as Transfecting Agent  
After determining the working range of each particle design, it was necessary to evaluate 
the effectiveness of each particle by performing transfections using both DNA plasmid and 
siRNA. Once maximal binding ratios were established, transfections were performed using those 
ratios of nucleic acid to nanoparticles and higher ratios in order to find the ratio with maximal 
transfection efficiency. If this was found, further transfections were performed to find the 
optimal DNA concentration for transfection. This was then compared with a commonly used 
transfection agent, Lipofectamine™2000. 
For NaYF4-shell NPs, the binding ratio with DNA plasmid was experimentally determined 
as 7:1 μg of NPs to μg of DNA. This was determined prior to the design team taking on the 
project. As seen in Figure 8, measurable expression of GFP was observed with this ratio. GFP 
expression was used to indicate that the nucleic acid in complex with the particle is being 
transfected into the cell, is being released, and is still functional. Since there is a significant 
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amount of fluorescence beyond the background of particles alone, it can be inferred that the 
NaYF4-shell NPs effectively deliver nucleic acid into the cell and may protect it from 
degradation. Once inside the cell, the particles are also releasing the DNA plasmid since it 
cannot be transcribed unless it is free. 
With the CaF2-shell NPs, a binding ratio of 80:1 μg NPs to μg DNA was determined via 
agarose gel (Figures 14 and 15). As seen in Figure 17, there was no measurable expression of 
GFP since the relative fluorescence is of the same magnitude as the NP control. This suggests 
that CaF2-shell NPs are getting into the cell since the background fluorescence of the particle is 
seen in both the NP control and the NP+DNA group. However, since GFP fluorescence was not 
observed beyond the fluorescence of the particle, GFP does not appear to be expressed - either 
because the DNA plasmid is not being released from the particle, or because it is being degraded 
before it can be expressed. 
A similar situation is seen for siRNA transfection measured as SOD1 knockdown (Figures 
10, 11, 18, 19, and 20). The NaYF4-shell NPs show effective transfection with a 45% 
knockdown of SOD1 (p<0.01) compared to the control. This shows effective delivery and 
protection of the siRNA. In contrast, the CaF2-shell NPs show no significant difference between 
the control group and the NP+siRNA group. This suggests that either the siRNA is not being 
released or is being degraded. It seems more likely that the CaF2-shell NPs are simply not 
releasing the nucleic acid because the binding ratios are so much higher. This shows a much 
greater affinity of nucleic acid for particle. However, further testing would need to be done to 
test this hypothesis. 
A proposed mechanism of release that would explain this situation is electrostatic stacking 
interactions that are strong enough to overcome the pH changes within the cell. Nucleic acid is 
complexed to the particles through electrostatic stacking interactions. The negatively-charged 
nucleic acids are attracted to the positively-charged particle surface. The particles then shield the 
negatively-charged nucleic acids from the negative surface of the cell, which allows the particle-
nucleic acid complex to enter into the cell via endocytosis. Once inside the cell, the particle-
nucleic acid complex would be exposed to lysosomes, which alter the pH within the endosome. 
With the NaYF4-shell particles, this pH change may have been enough to liberate the nucleic 
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acid. However, with the CaF2-shell particles, this pH change does not seem to overcome the 
stacking interactions. 
UCNPs as an ALS Treatment: A larger perspective 
Economics  
 As presented earlier, the only drug currently approved for treatment of ALS is Riluzole. 
Even with questions concerning its efficacy, the cost is unfavorable at roughly $17 per 50 mg 
pill, prior to insurance coverage. (Epocrates, 2012) If siRNA can be effectively delivered into 
motor neurons using UCNPs, the market value of this treatment is potentially beyond that of 
Riluzole. It is impossible to estimate exact figures for such a treatment. 
Environmental Impact  
With any new therapy, it is important to understand downstream effects of the disposal not 
only of the therapy itself but also of the materials associated with its manufacturing. The 
production of UCNPs requires the use of lanthanide salts. Ytterbium, erbium, and thulium, the 
current compounds used for doping, pose no environmental threat to plants or animals. They are 
considered biologically inert. Water-soluble compounds of yttrium are considered mildly toxic, 
mostly affecting aquatic animals. Therefore waste disposal in the manufacturing process would 
need to be monitored but no special licensing or permits need to be acquired. (Ytterbium Oxide, 
2010) (Erbium Oxide, 2008) 
Societal Influence  
ALS is a devastating disease that affects approximately 6,000 people in the U.S. annually. 
The development of a treatment for ALS would not only save the lives of these people but also 
reshape the lives of their families and friends. A siRNA delivery system could provide hope to 
thousands of people who are currently listed as terminal. 
Political Ramification  
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Until recently, ALS was rarely given much attention by the public. The most common 
association is with Major League Baseball Hall of Famer Lou Gehrig, who retired from the game 
at the age of 36 because of the disease. However, in early 2011, former Massachusetts Governor 
Paul Cellucci was diagnosed with a slow progressing form of the disease bringing ALS to the 
forefront of the public attention. Governor Cellucci has put forward the goal of raising $10 
million for ALS research at UMass Medical School in Worcester. (Phillips, 2011) This project is 
a direct result of that funding. 
Health and Safety  
Safety was a major objective of the design and so has been addressed with toxicity analyses 
in vitro. The next step is to move into organismal models to ensure that the toxicity to specific 
tissues is not inhibitory to the use of UCNPs as a delivery vector for siRNA. As for any 
treatment, the health and safety of the patient is of utmost importance. The ultimate goal would 
be to target delivery of siRNA specifically to the motor neurons so that normal SOD1 in other 
tissues would not be affected. This would allow the treatment to specifically target a root cause 
of ALS, benefiting the most patients without negatively affecting the health of any other organ 
system. Whether or not this would lead to a restoration of motor function already lost by the 
patient remains to be seen. The goal is to stop progression. 
Ethical Concern  
The whole point of this project is to stop the progression of, or even reverse, the effects of a 
devastating degenerative disease. This would directly improve the lives of all patients receiving 
the treatment. Some ethical concerns that do come out of this are marketing, administration, and 
availability of the treatment. Marketing needs to be carefully monitored so that the expectations 
of patients do not exceed the limitations of the treatment. Patients need to be informed of exactly 
what the treatment does and when it is most effective or not effective at all so that they and their 
doctors can make an informed decision on whether to use this treatment. Administration of the 
treatment also has to be carefully constructed so as not to leave the patient in a worse condition. 
Any treatment targeting the central nervous tissue has to be carefully calibrated due to the 
sensitivity and importance of such structures. The next step of development for this system 
would use animal models to address this issue of administration. Since ALS is not a common 
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disease, cases are greatly dispersed across a global market. A viable treatment would need to be 
made available on multiple continents and would have to be accessible at varying socio-
economic statuses. Therefore efforts must be made to keep production costs at a minimum while 
securing the proper approvals in multiple international markets. 
Sustainability  
The design of UCNPs has little effect on the environment. However, the manufacture of 
UCNPs on a large scale will require energy and material input. The manufacturing process can 
be made sustainable by drawing that energy and material from sustainable sources, such as solar 
power generators or low impact mining operations. 
Manufacturability of UCNPs  
As of now, UCNPs have only been used in very small quantities in a laboratory setting. 
Production of UCNPs has been tailored to meet the needs of this scale. Only small quantities of 
NPs are produced in 100-mL flasks (40-100 mg yield) at relatively low concentrations (0.1-10 
mg/mL). If this is going to become a marketable treatment, production will have to meet the 
demands of a global market. Things to consider when manufacturing UCNPs on a large scale are 
scale of the production; cost of production, including initial materials and final yields; and 
difficulties of production, such as waste disposal and reaction conditions. First, the current 
process will be described and then broken down for manufacturability. 
 Currently, the manufacturing process of UCNPs is broken down into 4 steps, (1) assembly 
of the core/shell particle, (2) ligand exchange, (3) PEI conjugation, and (4) sterilization followed 
by centrifugation. The assembly of the core/shell particle is performed at high temperature (310O 
C) in an inert atmosphere (argon gas) using an organic solvent (oleic acid). Since the shell of the 
particle is positively charged, the polar head of the oleic acid shields the particles from the 
nonpolar solvent. The core/shell are fully assembled but the linkage to oleic acid keeps the 
particle from being water-soluble. Toluene is used to scrub the particles from the oleic acid and 
transfer them into a partially polar environment (diethylene glycol). The solution is heated to 240 
O C in the presence of citric acid. The toluene is boiled off and the oleic acid is replaced with 
citric acid making the particles water-soluble. The particles can then be suspended in an aqueous 
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solution of dimethyl sulfoxide and phosphate buffered saline at room temperature (22 O C). 
Aziridines are then added as precursors for branched polyethyleneimine (PEI). These link to the 
citric acid forming PEI-coated nanoparticles. The fully formed UCNPs are then sterilized by 
autoclave and then centrifuged to remove any excess PEI. This typically results in an 80% yield 
before centrifugation. (Production methods were drawn from the protocol developed by Shen, Jie 
of the Han Laboratory) 
 Cost of production is influenced by the initial cost of the material, the means of production, 
the amount produced per batch, and the final yield. The solvents and conjugates used are 
common and can be attained easily. The limiting material cost is the lanthanide metals used to 
form the core of the particle. However, recycling of the waste from the particle assembly and 
subsequent steps could lead to recovery of precursors and reduce overall costs. The means of 
production and the batch size are linked. Currently, the particles are produced in a laboratory 
using glassware assembled on-site. Increasing the batch size would require larger containers that 
can still maintain high temperatures and pressure. The most cost-effective solution would likely 
be batch reactors which are easily designed and maintained, widely used in industry and thereby 
readily available, and meet the specifications for temperature and pressure ranges associated with 
each step of the synthesis. Much like quantum dots, the industry demand for these particles 
would be on the one- to fifty-milligram scale per client. Therefore, the batch size would likely be 
less than five liters (minimally yielding two grams of UCNPs). Recycling the waste and using 
batch reactors to maintain reaction conditions would address the difficulties of production.    
 MQP Report 52 
Chapter 7: Final Design and Validation  
A need exists for an effective ALS therapy. Knockdown of mutated Superoxide Dismutase 
1 has been proposed as a novel approach to disrupting the progression of ALS. Herein we 
proposed a design that utilizes RNAi to achieve this potentially therapeutic inhibition, however 
the delivery of siRNA presents challenges regarding safety, scalability, efficacy, and specificity. 
Thus, the specific objectives of this study were to assess the application of novel UCNPs as 
siRNA delivery vectors in these particular aspects. In order, their priority was determined to 
evaluate the success of the design: 




It is important to note that while the achievement of each objective was evaluated directly 
by specific assays, objective priority did not determine the order in which the experiments were 
conducted. Instead, experiments were conducted in order of increasing complexity, as the results 
of simple experiments would guide the parameters chosen for the more complex procedures. 
Below, experiments are described in the chronological order in which they were performed, with 
the reasoning for choosing such order. 
1. Safety was evaluated first because its measureable outcome had a design constraint; the 
cytotoxic effects of the particle dose could not compromise cell viability below 90%. As such, 
cytotoxicity assays were the first experiments conducted to ensure future experiments fell within 
tolerable particle dosages.  
2. Following cytotoxicity assays, the binding ratios for plasmid and siRNA conjugation to 
NPs were derived. These assays provided specifications regarding the maximum payload 
saturation that could be delivered per NP. In effect, data from these tests enabled the team to 
scale the treatment to any desired quantity while maintaining maximum design efficiency.  
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3. The plasmid transfection experiment was performed next, to gauge the efficacy of the 
design. Specifically, measurable expression of GFP would indicate the efficacy of the delivery 
system compared to the control agent, lipofectamine.  
4. In parallel with the plasmid transfection, siRNA transfections were performed to 
evaluate to final objective; specificity. The siRNA transfection provided samples with which 
Western blot analysis could be conducted. The analysis ultimately verified the specificity of 
treatment against the target protein, SOD1, as well as the efficacy of its silencing.   
The cell line chosen to conduct these studies was the HeLa human cervical cancer line. 
Unless otherwise noted, all cultures were maintained and prepared using antibiotic-free, DMEM 
+10% FBS. All assays were performed in standard tissue culture polystyrene, and incubated at 
37° C and 5% CO2. All cell counts were determined by hemocytometer count without trypan 
blue exclusion staining.   
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Chapter 8: Conclusions and Recommendations  
Conclusions  
The experimental approach demonstrated several features regarding NaYF4-shell UCNP 
activity in vitro. First, cytotoxicity assays characterized the workable range for NaYF4-shell 
UCNP transfection, which was found to tolerate concentrations up to 20 µg/mL while 
maintaining 80% cell viability. This finding was followed by the demonstration of effective 
plasmid transfection quantified in correlation with GFP expression, which was 45% of the 
positive control, Lipofectamine™. Upon effective plasmid transfection, siRNA transfection 
verified payload protection through successful SOD1 knockdown. Relative to the PBS control, 
45% knockdown was achieved.  
CaF2-shell UCNPs demonstrated a cytotoxicity profile with an improved range of tolerance 
compared to the NaYF4 UCNPs. Cells were found to tolerate concentrations up to 50 µg/mL 
while maintaining 80% cell viability. While CaF2-shell UCNPs could bind plasmid DNA, they 
did not demonstrate GFP expression upon transfection, suggesting insufficient intracellular 
payload release. Transfection with siRNA yielded similar results; although CaF2-shell UCNPs 
were found to complex with siRNA at a 30:1 molar ratio (siRNA:UCNP), no significant 
(p>0.05) target knockdown was achieved.  
Despite the shortcomings of the CaF2-shell design, the NaYF4-shell design demonstrated 
that UCNPs have potential as transfecting agents, in addition to their other valuable properties 
for imaging and tracking applications. Continued research and characterization with UCNPs 
could overcome the limitations in toxicity and transfection efficiency that are exhibited by the 
preliminary and final designs respectively.  
 The implication of SOD1 across all forms of ALS represents an opportunity for the 
application of RNAi –based therapy. Treatment with sequence specific siRNAs and UCNPs may 
target the cause of ALS, and if successful, could give rise to a model approach for treating other 
neurodegenerative disorders.      
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Recommendations  
This study was limited in scope by time, UCNP availability, access to a single cell line, and 
small sample sizes. The following recommendations could be implemented in future studies to 
expand the current characterization of UCNPs for ALS therapy: 
 
1. Determine the cause for decreased transfection capacity in CaF2-shell UCNPs. 
Current data suggests that electrostatic payload-particle interactions are too strong to 
support delivery. Surface chemistry could be modified to allow for a similar binding 
ratio, with increased payload delivery.  
2. Repeat experiments in alternative cell lines. ALS is a disease that affects the afferent 
motor neurons; ideally UCNPs should be tested in a neuronal cell line in vitro, to better 
characterize their efficacy prior to in vivo studies.  
3. Perform experiments with greater sample size. To improve the consistency and 
accuracy of the data, the sample sizes should be increased. This is particularly pertinent 
regarding Western blotting, which can only be performed with 12 samples per blot.   
4. Utilize confocal microscopy to confirm endocytosis. At this point it can only be 
assumed that successful GFP expression and SOD1 knockdown are the direct result of 
intracellular payload delivery by UCNPs. However, direct microscopic evidence would 
confirm UCNP endocytosis as the mechanism of delivery.  
5. Conduct ζ-potential and particle size measurements. The ζ-potential is an indirect 
measure of surface charge and dispersion stability. Understanding how these properties 
affect UCNP functionality, could improve and guide the development of UCNPs for 
specific or alternative applications.   
6. Characterize the upconversion effect in vitro. Confirm that UCNPs retain their 
upconverting properties after entering the cell. This could allow particle tracking to 
determine where the particles are being taken up (e.g., the spinal column and the 
corticospinal motor neurons).
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Glossary 
 
ALS – Amyotrophic Lateral Sclerosis 
DMEM – Delbucco’s Modified Eagle Medium 
EtBr – Ethidium Bromide 
fALS – Familial ALS 
FBS – Fetal Bovine Serum 
GFP – Green fluorescent protein 
HRP – Horseradish Peroxidase 
NIH – National Institute of Health 
NINDS – National Institute of Neurological Disorders and Stroke 
NP – Nanoparticle 
PBS – Phosphate Buffered Saline 
PCC – Pairwise Comparison Chart 
PEI – Polyethylene Imine 
RNAi – RNA interference 
sALS – Sporadic ALS 
siRNA – small interfering RNA 
SOD1 – Superoxide Dismutase 1 
UCNP – Upconverting Nanoparticle 
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Figure 21: Objectives Tree The objectives tree organizes the primary and secondary objectives of the final design. In the first row the primary objectives are arranged. Below each primary objective, secondary sub-objectives follow. For example; for the primary objective of Safety, the sub-objectives detail that the design be safe for the user delivering the therapy and the cells receiving the therapy.  
To measure efficacy, the extent of protein knockdown is of highest priority. Second is the ability of the therapy to penetrate the cell, and of least priority is the efficacy in comparison to other delivery methods. 
Table 2: PCC for Efficacy Sub-objectives 















The highest priority for scalability is that the design be scalable to in vivo models. Next, the design should be scalable to multiple cell lines, and least importantly to multiple doses. 
Specificity to target the protein is of higher priority than to target the cell. 
The safety of the user is of higher priority than the safety of the cells receiving the therapy. 
Table 3: PCC for Sub-Objective – Scalable 
Table 4: PCC for Sub-Objective- Specific 
Table 5: PCC for Sub-Objective – Safe 
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Appendix B: Lab Protocols 
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Western Blotting for siRNA Transfection 
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